One study in healthy adults with normal coagulation (blood clotting) status found that daily supplementation with 1,000 IU (670 mg) of RRR --tocopherol for 12 weeks decreased -carboxylation of prothrombin, a vitamin K-dependent factor in the coagulation cascade (127)
GLP-1R agonists effects on cardiovascular events The first pieces of evidence of the potential clinical benefit of GLP-1 agonists have emerged recently, pointing to a decrease of major adverse cardiovascular and cerebrovascular events (MACCE) including stroke, MI, cardiac mortality, acute coronary syndrome, and revascularization procedures
Phase 2 trial data for the CagriSema combination (cagrilintide 2.4mg + semaglutide 2.4mg) demonstrated approximately 15.6% mean weight reduction at 32 weeks substantially exceeding semaglutide alone and positioning amylin/GLP-1 dual agonism as a competitive research frontier alongside GIP/GLP-1 and triple agonist approaches
Individuals should weigh the risks and benefits, as well as discuss alternatives, with their physicians
